JP2022529312A - 低用量の三重複合製剤 - Google Patents

低用量の三重複合製剤 Download PDF

Info

Publication number
JP2022529312A
JP2022529312A JP2021556883A JP2021556883A JP2022529312A JP 2022529312 A JP2022529312 A JP 2022529312A JP 2021556883 A JP2021556883 A JP 2021556883A JP 2021556883 A JP2021556883 A JP 2021556883A JP 2022529312 A JP2022529312 A JP 2022529312A
Authority
JP
Japan
Prior art keywords
dose
pharmaceutical composition
diabetes
composition according
metformin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021556883A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529312A5 (https=
JPWO2020194046A5 (https=
Inventor
ロジャース，アンソニー
マクマホン，ステファン
Original Assignee
ザ ジョージ インスティテュート フォー グローバル ヘルス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ジョージ インスティテュート フォー グローバル ヘルス filed Critical ザ ジョージ インスティテュート フォー グローバル ヘルス
Publication of JP2022529312A publication Critical patent/JP2022529312A/ja
Publication of JP2022529312A5 publication Critical patent/JP2022529312A5/ja
Publication of JPWO2020194046A5 publication Critical patent/JPWO2020194046A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021556883A 2019-03-25 2020-03-25 低用量の三重複合製剤 Pending JP2022529312A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962823575P 2019-03-25 2019-03-25
US62/823,575 2019-03-25
PCT/IB2020/000141 WO2020194046A1 (en) 2019-03-25 2020-03-25 Low-dose triple combination formulation

Publications (3)

Publication Number Publication Date
JP2022529312A true JP2022529312A (ja) 2022-06-21
JP2022529312A5 JP2022529312A5 (https=) 2023-04-05
JPWO2020194046A5 JPWO2020194046A5 (https=) 2023-04-05

Family

ID=72611638

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021556883A Pending JP2022529312A (ja) 2019-03-25 2020-03-25 低用量の三重複合製剤

Country Status (11)

Country Link
US (1) US20220184070A1 (https=)
EP (1) EP3946343A4 (https=)
JP (1) JP2022529312A (https=)
KR (1) KR20220004026A (https=)
CN (1) CN113905738A (https=)
AU (1) AU2020245801A1 (https=)
BR (1) BR112021018973A2 (https=)
CA (1) CA3134799A1 (https=)
MX (1) MX2021011745A (https=)
TW (1) TW202102208A (https=)
WO (1) WO2020194046A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12077118B2 (en) 2019-05-09 2024-09-03 Mack Rides Gmbh & Co. Kg Locking device for a safety bar, passenger accommodation and amusement ride having a locking device of this kind

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7830433B2 (ja) * 2020-09-02 2026-03-16 ラボラトリオス シラネス、エセ．ア．デ セ．べ． ２型真性糖尿病の制御及び管理のための配合薬剤
CN113559088A (zh) * 2021-01-21 2021-10-29 江苏宇锐医药科技有限公司 一种含二甲双胍和西格列汀的复方降糖药物制剂
WO2024043358A1 (ko) * 2022-08-24 2024-02-29 동아에스티 주식회사 에보글립틴 및 메트포르민을 포함하는 경구용 복합제제 및 그의 제조방법
WO2025090920A1 (en) * 2023-10-25 2025-05-01 Piton Therapeutics, Inc. Compositions and methods for treating dysfunction of glucose metabolism and/or regulation
CN117599008A (zh) * 2023-11-14 2024-02-27 华中药业股份有限公司 一种西格列汀二甲双胍缓释片及其制作方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012517977A (ja) * 2009-02-13 2012-08-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害剤（リナグリプチン）を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬
JP2018052945A (ja) * 2005-09-29 2018-04-05 ノバルティス アーゲー 新規製剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1008560B1 (pt) * 2009-02-13 2021-08-31 Boehringer Ingelheim International Gmbh Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dpp-iv e opcionalmente um outro agente antidiabético e usos dos mesmos
US20160151382A1 (en) * 2013-10-08 2016-06-02 Kevin Ray Pickering Cooperative Medication Combination Systems
US20160067217A1 (en) * 2014-09-09 2016-03-10 ARKAY Therapeutics, LLC Metabolic syndrome treatment
KR20180002460A (ko) * 2016-06-29 2018-01-08 주식회사 엘지화학 제2형 당뇨병 및 당뇨성 이상지질혈증 치료용 조성물, 키트 및 병용 요법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018052945A (ja) * 2005-09-29 2018-04-05 ノバルティス アーゲー 新規製剤
JP2012517977A (ja) * 2009-02-13 2012-08-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害剤（リナグリプチン）を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
INT J CLIN PRACT, vol. 66, no. 5, JPN6024013261, 2012, pages 465 - 476, ISSN: 0005452166 *
JAPANESE CLINICAL MEDICINE, vol. 3, JPN6024013260, 2012, pages 1 - 7, ISSN: 0005452165 *
医療薬学, vol. 39, no. 5, JPN6024013262, 2013, pages 309 - 321, ISSN: 0005452167 *
糖尿病, vol. Vol.55, Suppl.1, JPN6024013263, pages 123, ISSN: 0005452168 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12077118B2 (en) 2019-05-09 2024-09-03 Mack Rides Gmbh & Co. Kg Locking device for a safety bar, passenger accommodation and amusement ride having a locking device of this kind

Also Published As

Publication number Publication date
AU2020245801A1 (en) 2021-11-11
CA3134799A1 (en) 2020-10-01
US20220184070A1 (en) 2022-06-16
TW202102208A (zh) 2021-01-16
EP3946343A4 (en) 2022-12-28
WO2020194046A1 (en) 2020-10-01
CN113905738A (zh) 2022-01-07
KR20220004026A (ko) 2022-01-11
MX2021011745A (es) 2021-10-22
EP3946343A1 (en) 2022-02-09
BR112021018973A2 (pt) 2022-02-01

Similar Documents

Publication Publication Date Title
JP2022529312A (ja) 低用量の三重複合製剤
JP2022529208A (ja) 低用量の三重複合製剤
KR20150013838A (ko) 당뇨병 치료를 위한 글루코키나아제 활성화제 조성물
EP1351683B1 (en) Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
US20070287669A1 (en) Combined Use of Derivatives of GLP-1 Analogs and PPAR Ligands
WO2002069994A2 (en) Combined use of derivatives of glp-1 analogs and ppar ligands
TWI519297B (zh) 使用雙醋瑞因之糖尿病輔助療法
KR102760956B1 (ko) 제미글립틴 및 다파글리플로진을 포함하는 경구용 복합제제, 및 이의 제조 방법
EP1935424A1 (en) Pharmaceutical compositions comprising combined antidiabetic substances for use in diabetes mellitus
BG64892B1 (bg) Комбинация от тиазолидиндион и сулфонилуреа, фармацевтичен състав и използване
US8106081B2 (en) Combination of organic compounds useful for treating diabetes
HK40067219A (zh) 低剂量三联组合制剂
HK40124034A (zh) 低剂量三联组合制剂
HK40067275A (zh) 低剂量三联组合制剂
KR20220140343A (ko) 에보글립틴 및 메트포르민을 포함하는 경구용 복합제제 및 그의 제조방법
JPWO2002028398A1 (ja) 糖尿病治療用組成物
HK1160031B (en) Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-iv, and other antidiabetic or antiobesity agents as active ingredients
HK1137345A (en) Combination treatment for diabetes mellitus
HK1108359B (en) Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
EP1368055A2 (en) Combined use of derivatives of glp-1 analogs and ppar ligands
HK1102424B (en) Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
HK1117735A (en) Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211210

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20221216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240408

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240704

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240820

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241105